Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
ConditionDry Eye Disease (DED)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorHuons Co., Ltd.
About this trial
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
Eligibility criteria
Qualifiers
Adults aged ≥ 19 years at the time of screening
Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening
OSDI score ≥ 23 at the time of screening
Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial
Disqualifiers
Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results
Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes
Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome
Trial participants with a history of corneal transplantation or neurotrophic keratitis
Trial design
Treatments tested in this trial
- HUC1-394
- Placebo
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov